ArticleRisk management and healthcare policy2025
Pharmacists' Opinions on the Policy for Controlling the Sale of Drugs That Have Been Abused in Thailand.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Medication abuse is a major global issue due to its health risks. In Thailand, regulation of drug sales is overseen by the Thai Food and Drug Administration (FDA). This study aimed to examine pharmacists' opinions on policies regarding the control and monitoring of the sales of drug that have been abused in Thailand. Methods: A mixed-method design was employed, combining a survey of 440 pharmacy pharmacists and 77 regulatory enforcement pharmacists selected through accidental sampling with in-depth interviews of 17 pharmacists recruited via purposive and snowball sampling until data saturation. Survey data were analyzed descriptively, while interview data were examined using content analysis. Data were collected nationwide in Thailand between April and October 2023. Results: Over 80% of respondents understood the policy measures, yet most reported limited effectiveness and unintended consequences. Nearly 90% indicated that maintaining drug sales records drives high-risk buyers to underground markets while increasing workloads and leading some pharmacies to discontinue sales. Respondents favored eliminating or digitalizing records. The FDA Reporter system was viewed as useful, but incomplete and retrospective data limited its effectiveness. Participants recommended real-time integration across the supply chain. Restrictions on retail and wholesale quantities were considered only partially effective, often burdening patients requiring continuous treatment. By contrast, requiring pharmacists to comply with Good Pharmacy Practice (GPP) and personally dispense dangerous drugs was regarded as the most effective measure. Interviews also align with the survey and highlighted persistent issues such as "hanging-license pharmacies" and emphasized stricter enforcement, intersectoral collaboration, and education for at-risk groups. Conclusion: Current measures to control drug sales remain ineffective, leading to diversion, increased workloads, and discontinued sales. Enforcing Good Pharmacy Practice (GPP) has proven more effective. Policy strengthening should focus on modernizing electronic reporting, eliminating rigid quantity limits, and enforcing pharmacist presence during operating hours for safe, responsible drug distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.